Summary of adverse events
| 1100 mg AMG 820 + 200 mg pembrolizumab (n=98) | 1400 mg AMG 820 + 200 mg pembrolizumab (n=18) | All patients (N=116) | |
| All TEAEs, n (%) | 97 (99.0) | 18 (100.0) | 115 (99.1) |
| Grade ≥3 | 87 (88.8) | 15 (83.3) | 102 (87.9) |
| Grade ≥4 | 23 (23.5) | 4 (22.2) | 27 (23.3) |
| Serious AEs | 60 (61.2) | 10 (55.6) | 70 (60.3) |
| Leading to discontinuation of AMG 820 | 11 (11.2) | 3 (16.7) | 14 (12.1) |
| Leading to discontinuation of pembrolizumab | 12 (12.2) | 3 (16.7) | 15 (12.9) |
| Fatal AEs | 5 (5.1) | 1 (5.6) | 6 (5.2) |
| Treatment-related TEAEs, n (%) | 85 (86.7) | 17 (94.4) | 102 (87.9) |
| Grade ≥3 | 58 (59.2) | 10 (55.6) | 68 (58.6) |
| Grade ≥4 | 13 (13.3) | 3 (16.7) | 16 (13.8) |
| Serious AEs | 25 (25.5) | 8 (44.4) | 33 (28.4) |
| Leading to discontinuation of AMG 820 | 9 (9.2) | 3 (16.7) | 12 (10.3) |
| Leading to discontinuation of pembrolizumab | 10 (10.2) | 3 (16.7) | 13 (11.2) |
| Fatal AEs | 1 (1.0) | 1 (5.6) | 2 (1.7) |
Analysis of safety included patients who received at least one dose of AMG 820 plus pembrolizumab.
AE, adverse event; TEAE, treatment-emergent adverse event.